Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders
ABSTRACTObjective To analyze the current treatment status and prognostic regression of the chronic NK cell lymphoproliferative disorder (CLPD-NK).Methods We retrospectively analyzed the clinical features, treatment and prognosis of 18 patients with CLPD-NK who were treated at our Hospital between Se...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2307817 |
| _version_ | 1797322844362768384 |
|---|---|
| author | Dong-lin Liu Yan-jie Wang Si-yu Qian Shan-shan Ma Meng-jie Ding Meng Dong Jie-ming Zhang Ming-zhi Zhang Qing-jiang Chen Xu-dong Zhang |
| author_facet | Dong-lin Liu Yan-jie Wang Si-yu Qian Shan-shan Ma Meng-jie Ding Meng Dong Jie-ming Zhang Ming-zhi Zhang Qing-jiang Chen Xu-dong Zhang |
| author_sort | Dong-lin Liu |
| collection | DOAJ |
| description | ABSTRACTObjective To analyze the current treatment status and prognostic regression of the chronic NK cell lymphoproliferative disorder (CLPD-NK).Methods We retrospectively analyzed the clinical features, treatment and prognosis of 18 patients with CLPD-NK who were treated at our Hospital between September 2016 and September 2022.Results Eighteen patients were included: three patients were treated with chemotherapy, five patients underwent immune-related therapy, one patient was treated with glucocorticoids alone, five patients were administered granulocyte colony-stimulating factor, blood transfusion therapy, or anti-infection therapy, followed by observation and follow-up, and four patients were observed without treatment. Fifteen patients survived, including two patients who achieved complete remission (CR) and seven patients who achieved partial remission (PR), of whom one patient progressed to Aggressive NK-cell leukemia (ANKL) and sustained remission after multiple lines of treatment; three patients were not reviewed, of which one patient was still in active disease, three patients developed hemophagocytic syndrome during treatment and eventually died, one of them had positive Epstein–Barr virus (EBV) expression. The 5-years overall survival rate was 83%.Conclusion Most patients with CLPD-NK have inert progression and a good prognosis, whereas some patients have a poor prognosis after progressing to ANKL and combined with hemophagocytic syndrome. Abnormal NK cells invading the center suggest a high possibility of ANKL development, and immunosuppressants and hormones are effective treatments for this disease. |
| first_indexed | 2024-03-08T05:20:07Z |
| format | Article |
| id | doaj.art-94053c7500624e3bb73510de997def95 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-08T05:20:07Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-94053c7500624e3bb73510de997def952024-02-06T13:56:18ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2307817Clinical features and prognosis of chronic natural killer cell lymphoproliferative disordersDong-lin Liu0Yan-jie Wang1Si-yu Qian2Shan-shan Ma3Meng-jie Ding4Meng Dong5Jie-ming Zhang6Ming-zhi Zhang7Qing-jiang Chen8Xu-dong Zhang9Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaABSTRACTObjective To analyze the current treatment status and prognostic regression of the chronic NK cell lymphoproliferative disorder (CLPD-NK).Methods We retrospectively analyzed the clinical features, treatment and prognosis of 18 patients with CLPD-NK who were treated at our Hospital between September 2016 and September 2022.Results Eighteen patients were included: three patients were treated with chemotherapy, five patients underwent immune-related therapy, one patient was treated with glucocorticoids alone, five patients were administered granulocyte colony-stimulating factor, blood transfusion therapy, or anti-infection therapy, followed by observation and follow-up, and four patients were observed without treatment. Fifteen patients survived, including two patients who achieved complete remission (CR) and seven patients who achieved partial remission (PR), of whom one patient progressed to Aggressive NK-cell leukemia (ANKL) and sustained remission after multiple lines of treatment; three patients were not reviewed, of which one patient was still in active disease, three patients developed hemophagocytic syndrome during treatment and eventually died, one of them had positive Epstein–Barr virus (EBV) expression. The 5-years overall survival rate was 83%.Conclusion Most patients with CLPD-NK have inert progression and a good prognosis, whereas some patients have a poor prognosis after progressing to ANKL and combined with hemophagocytic syndrome. Abnormal NK cells invading the center suggest a high possibility of ANKL development, and immunosuppressants and hormones are effective treatments for this disease.https://www.tandfonline.com/doi/10.1080/16078454.2024.2307817Chronic NK-cell lymphoproliferative disordersclinical featuresprognosis |
| spellingShingle | Dong-lin Liu Yan-jie Wang Si-yu Qian Shan-shan Ma Meng-jie Ding Meng Dong Jie-ming Zhang Ming-zhi Zhang Qing-jiang Chen Xu-dong Zhang Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders Hematology Chronic NK-cell lymphoproliferative disorders clinical features prognosis |
| title | Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders |
| title_full | Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders |
| title_fullStr | Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders |
| title_full_unstemmed | Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders |
| title_short | Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders |
| title_sort | clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders |
| topic | Chronic NK-cell lymphoproliferative disorders clinical features prognosis |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2307817 |
| work_keys_str_mv | AT donglinliu clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT yanjiewang clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT siyuqian clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT shanshanma clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT mengjieding clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT mengdong clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT jiemingzhang clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT mingzhizhang clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT qingjiangchen clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders AT xudongzhang clinicalfeaturesandprognosisofchronicnaturalkillercelllymphoproliferativedisorders |